Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2019 August;60(4) > The Journal of Cardiovascular Surgery 2019 August;60(4):456-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  RECENT DEVELOPMENTS IN DES FOR LONG LESIONS 

The Journal of Cardiovascular Surgery 2019 August;60(4):456-9

DOI: 10.23736/S0021-9509.19.10953-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Drug-coated balloons versus drug-eluting stents in the femoropopliteal artery: comparing apples to oranges?

Gary M. ANSEL

Vascular Services, OhioHealth, Columbus, OH, USA



Superficial femoral and popliteal artery disease are commonly involved in the development of symptomatic PAD. As time has gone on drug coated stents and drug coated balloons have supplanted the plain balloon angioplasty corner stone of therapy with superiority proven in randomized trials. Device approval trials are typically characterized by simple lesions that are less common than the longer complex disease. Registry data has demonstrated benefit of both technologies though drug coated balloons typically require a significant amount of adjunctive stenting in more complex disease. Recently published randomized data is starting to help proceduralists define when each therapy may be more optimal.


KEY WORDS: Angioplasty; Drug-eluting stents; Balloon angioplasty; Peripheral arterial disease

top of page